Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites

PURPOSEThis study was performed to assess the safety, efficacy, and clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) creation for treatment of medically refractory ascites and to identify prognostic factors for clinical response, morbidity, and mortality. MATERIALS AND METHO...

Full description

Bibliographic Details
Main Authors: Ahmad Parvinian, James T. Bui, M. Grace Knuttinen, Jeet Minocha, Ron C. Gaba
Format: Article
Language:English
Published: Galenos Publishing House 2014-01-01
Series:Diagnostic and Interventional Radiology
Online Access: http://www.dirjournal.org/archives/archive-detail/article-preview/transjugular-intrahepatic-portosystemic-shunt-for-/56402
_version_ 1797691401188671488
author Ahmad Parvinian,
James T. Bui,
M. Grace Knuttinen,
Jeet Minocha,
Ron C. Gaba
author_facet Ahmad Parvinian,
James T. Bui,
M. Grace Knuttinen,
Jeet Minocha,
Ron C. Gaba
author_sort Ahmad Parvinian,
collection DOAJ
description PURPOSEThis study was performed to assess the safety, efficacy, and clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) creation for treatment of medically refractory ascites and to identify prognostic factors for clinical response, morbidity, and mortality. MATERIALS AND METHODSIn this retrospective study, 80 patients (male:female, 52:28; mean age, 56 years; mean Model for End-Stage Liver Disease [MELD] score, 15.1) who underwent elective TIPS creation for refractory ascites between 1999–2012 were studied. A medical record review was performed to identify data on demographics, liver disease, procedures, and outcome. The influence of these parameters on 30-day, 90-day, and one-year mortality was assessed using binary logistic regression. Overall survival was analyzed with Kaplan-Meier statistics. RESULTSTIPS was successfully created using covered (n=70) or bare metal (n=10) stents. Hemodynamic success was achieved in all cases. The mean final portosystemic pressure gradient (PSG) was 6.8 mmHg. Thirty-day complications included mild encephalopathy in 35% of patients. Clinical improvement in ascites occurred in 78% of patients, with complete resolution or a ≥50% decrease in 66% of patients. No predictors of response or optimal PSG threshold were identified. The 30-day, 90-day, and one-year mortality rates were 14%, 23%, and 33%, respectively. Patient age (P = 0.026) was associated with 30-day mortality, while final PSG was associated with 90-day (P = 0.020) and one year (P = 0.032) mortality. No predictors of overall survival were identified. CONCLUSIONTIPS creation effectively treats medically refractory ascites with nearly 80% efficacy. The incidence of mild encephalopathy is nontrivial. Older age and final PSG are associated with mortality, and these factors should be considered in patient selection and procedure performance.
first_indexed 2024-03-12T02:13:45Z
format Article
id doaj.art-056e93a02971496380ff88aaf22f7eff
institution Directory Open Access Journal
issn 1305-3825
1305-3612
language English
last_indexed 2024-03-12T02:13:45Z
publishDate 2014-01-01
publisher Galenos Publishing House
record_format Article
series Diagnostic and Interventional Radiology
spelling doaj.art-056e93a02971496380ff88aaf22f7eff2023-09-06T11:15:36ZengGalenos Publishing HouseDiagnostic and Interventional Radiology1305-38251305-36122014-01-01201586410.5152/dir.2013.1313113049054Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascitesAhmad Parvinian,James T. Bui,M. Grace Knuttinen,Jeet Minocha,Ron C. GabaPURPOSEThis study was performed to assess the safety, efficacy, and clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) creation for treatment of medically refractory ascites and to identify prognostic factors for clinical response, morbidity, and mortality. MATERIALS AND METHODSIn this retrospective study, 80 patients (male:female, 52:28; mean age, 56 years; mean Model for End-Stage Liver Disease [MELD] score, 15.1) who underwent elective TIPS creation for refractory ascites between 1999–2012 were studied. A medical record review was performed to identify data on demographics, liver disease, procedures, and outcome. The influence of these parameters on 30-day, 90-day, and one-year mortality was assessed using binary logistic regression. Overall survival was analyzed with Kaplan-Meier statistics. RESULTSTIPS was successfully created using covered (n=70) or bare metal (n=10) stents. Hemodynamic success was achieved in all cases. The mean final portosystemic pressure gradient (PSG) was 6.8 mmHg. Thirty-day complications included mild encephalopathy in 35% of patients. Clinical improvement in ascites occurred in 78% of patients, with complete resolution or a ≥50% decrease in 66% of patients. No predictors of response or optimal PSG threshold were identified. The 30-day, 90-day, and one-year mortality rates were 14%, 23%, and 33%, respectively. Patient age (P = 0.026) was associated with 30-day mortality, while final PSG was associated with 90-day (P = 0.020) and one year (P = 0.032) mortality. No predictors of overall survival were identified. CONCLUSIONTIPS creation effectively treats medically refractory ascites with nearly 80% efficacy. The incidence of mild encephalopathy is nontrivial. Older age and final PSG are associated with mortality, and these factors should be considered in patient selection and procedure performance. http://www.dirjournal.org/archives/archive-detail/article-preview/transjugular-intrahepatic-portosystemic-shunt-for-/56402
spellingShingle Ahmad Parvinian,
James T. Bui,
M. Grace Knuttinen,
Jeet Minocha,
Ron C. Gaba
Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites
Diagnostic and Interventional Radiology
title Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites
title_full Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites
title_fullStr Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites
title_full_unstemmed Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites
title_short Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites
title_sort transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites
url http://www.dirjournal.org/archives/archive-detail/article-preview/transjugular-intrahepatic-portosystemic-shunt-for-/56402
work_keys_str_mv AT ahmadparvinian transjugularintrahepaticportosystemicshuntforthetreatmentofmedicallyrefractoryascites
AT jamestbui transjugularintrahepaticportosystemicshuntforthetreatmentofmedicallyrefractoryascites
AT mgraceknuttinen transjugularintrahepaticportosystemicshuntforthetreatmentofmedicallyrefractoryascites
AT jeetminocha transjugularintrahepaticportosystemicshuntforthetreatmentofmedicallyrefractoryascites
AT roncgaba transjugularintrahepaticportosystemicshuntforthetreatmentofmedicallyrefractoryascites